A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
Hiroshi IshiguroNorikazu MasudaNobuaki SatoKenji HigakiTakashi MorimotoYasuhiro YanagitaMakiko MizutaniShoichiro OhtaniKoji KanekoTomomi FujisawaMasato TakahashiTakayuki KadoyaNobuki MatsunamiYutaka YamamotoShinji OhnoToshimi TakanoSatoshi MoritaSachiko Tanaka-MizunoMasakazu ToiPublished in: Breast cancer research and treatment (2020)
UMIN000003283 https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003873.